Interestingly, in B-ALL- and BCR-ABL-driven CML, inhibition of cyclin-dependent kinases (CDKs) has been shown to restrain glycolytic metabolism by a suggested mechanism involving downregulation of MYC and the rate-limiting enzymes GLUT1, HK2, and LDHA [224,225]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.